Repro Med Systems (NasdaqCM:KRMD) - Share price, News & Analysis

KRMD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

KRMD Stock Overview

Rewards

Revenue is forecast to grow 11.84% per year

Risk Analysis

Earnings are forecast to decline by an average of 0.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Repro Med Systems Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Repro Med Systems
Historical stock prices
Current Share Price	US$2.43
52 Week High	US$4.72
52 Week Low	US$1.82
Beta	0.40
1 Month Change	8.97%
3 Month Change	-13.21%
1 Year Change	-45.52%
3 Year Change	-15.63%
5 Year Change	417.02%
Change since IPO	5,975.00%

Shareholder Returns

	KRMD	US Medical Equipment	US Market
7D	24.0%	7.0%	6.6%
1Y	-45.5%	-23.7%	-18.5%

Return vs Industry: KRMD underperformed the US Medical Equipment industry which returned -25.1% over the past year.

Return vs Market: KRMD underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is KRMD's price volatile compared to industry and market?
KRMD volatility
KRMD Average Weekly Movement	12.6%
Medical Equipment Industry Average Movement	10.5%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KRMD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: KRMD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1980	77	Linda Tharby	https://www.korumedical.com

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates.

Repro Med Systems Fundamentals Summary

How do Repro Med Systems's earnings and revenue compare to its market cap?
KRMD fundamental statistics
Market Cap	US$109.93m
Earnings (TTM)	-US$5.82m
Revenue (TTM)	US$24.30m

4.5x

P/S Ratio

-18.7x

P/E Ratio

Is KRMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
KRMD income statement (TTM)
Revenue	US$24.30m
Cost of Revenue	US$10.14m
Gross Profit	US$14.16m
Other Expenses	US$19.98m
Earnings	-US$5.82m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	58.26%
Net Profit Margin	-23.96%
Debt/Equity Ratio	0.7%

How did KRMD perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is KRMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KRMD?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for KRMD. This is calculated by dividing KRMD's market cap by their current preferred multiple.
What is KRMD's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$109.93m

KRMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.8x
Enterprise Value/EBITDA	-15.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does KRMD's PS Ratio compare to its peers?

KRMD PS Ratio vs Peers

The above table shows the PS ratio for KRMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	25.2x

Forward PS

Price-To-Sales vs Peers: KRMD is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (25.2x).

Price to Earnings Ratio vs Industry

How does KRMD's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?

Price-To-Sales vs Industry: KRMD is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Medical Equipment industry average (3.8x)

Price to Sales Ratio vs Fair Ratio

What is KRMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KRMD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.5x
Fair PS Ratio	2.2x

Price-To-Sales vs Fair Ratio: KRMD is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Share Price vs Fair Value

What is the Fair Price of KRMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KRMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KRMD's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KRMD's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Repro Med Systems forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-0.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KRMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KRMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KRMD's revenue (11.8% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: KRMD's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KRMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Repro Med Systems performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-90.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KRMD is currently unprofitable.

Growing Profit Margin: KRMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: KRMD is unprofitable, and losses have increased over the past 5 years at a rate of 90.8% per year.

Accelerating Growth: Unable to compare KRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KRMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).

Return on Equity

High ROE: KRMD has a negative Return on Equity (-16.74%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Repro Med Systems's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: KRMD's short term assets ($33.9M) exceed its short term liabilities ($4.7M).

Long Term Liabilities: KRMD's short term assets ($33.9M) exceed its long term liabilities ($3.9M).

Debt to Equity History and Analysis

Debt Level: KRMD has more cash than its total debt.

Reducing Debt: Insufficient data to determine if KRMD's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KRMD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KRMD has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 48.9% each year.

Discover healthy companies

Dividend

What is Repro Med Systems's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate KRMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KRMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KRMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KRMD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KRMD has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure

CEO

Linda Tharby (53 yo)

1.17yrs

Tenure

US$829,059

Compensation

Ms. Linda M. Tharby serves as President and Chief Executive Officer at Repro Med Systems, Inc. since April 12, 2021 and serves as its Director since May 06, 2022. She is an experienced global medical devic...

CEO Compensation Analysis

Compensation vs Market: Linda's total compensation ($USD829.06K) is about average for companies of similar size in the US market ($USD758.64K).

Compensation vs Earnings: Insufficient data to compare Linda's compensation with company performance.

Leadership Team

Experienced Management: KRMD's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: KRMD's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: KRMD insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31